At ASCO, Allos Therapeutics, Inc. (Nasdaq: ALTH) reported updated data from the Company's pivotal Phase 2 PROPEL study of pralatrexate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE